1	Standardized Data Elements for Patients with Acute Pulmonary Embolism
2	
3	A Consensus Report from the Pulmonary Embolism Research Collaborative
4	
5	Kenneth Rosenfield, MD, MSc, Terry R. Bowers, MD ² , Christopher F. Barnett, MD, MPH ³ ,
6	George A. Davis, PharmD, BCPS ⁴ , Jay Giri, MD,MPH ⁵ , James M. Horowitz, MD ⁶ , Menno V.
7	Huisman, MD,PhD ⁷ , FESC ⁷ , Beverley J. Hunt OBE, MD ⁸ , Brent Keeling, MD, Jeffrey A. Kline,
8	MD ⁹ , Frederikus A. Klok, MD, PhD ⁷ , Stavros V. Konstantinides, MD ¹⁰ , Michelle T Lanno ¹⁴ ,
9	Robert Lookstein, MD, MHCDL ¹¹ , John M. Moriarty, MD ¹² , Fionnuala Ní Áinle, MD, PhD ¹³ ,
10	Jamie L. Reed, MS ¹⁴ , Rachel P. Rosovsky, MD, MPH ¹⁵ , Sara M. Royce PhD ¹⁶ , Eric A.
11	Secemsky, MD, MSc ¹⁷ , Andrew SP Sharp, MD ¹⁸ , Akhilesh K. Sista, MD ¹⁹ , Roy E. Smith, MD,
12	MS ²⁰ , Phil Wells, MD, MSc ²¹ Joanna Yang, BA ¹⁵ , Eleni M. Whatley, PhD ¹⁶
13	
14	On behalf of attendees at the inaugural PERC [™] meeting held in Washington DC on April 22,
15	2022 (See Appendix 2 for full listing)
-0 16	
10	AFFILIATIONS
18	
19 20	¹ Division of Cardiology, Massachusetts General Hospital, Boston, MA Massachusetts ² Corewell Health, Beaumont University Hospital, Division of Cardiovascular Medicine, Royal Oak, MI
20 21	³ Division of Cardiology, University of California, San Francisco, CA
21	
	⁴ University of Kentucky UK HealthCare; University of Kentucky College of Pharmacy, Lexington, KY ⁵ Cardiovascular Medicine Division, University of Pennsylvania Perelman School of Medicine
23	
24	⁶ NYU Langone Health, Department of Medicine, Division of Cardiology, New York, NY
25 26	⁷ Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
26	and Dutch Thrombosis Network
27	⁸ Kings Healthcare Partners, London UK
28	⁹ Wayne State University School of Medicine, Detroit, MI
29	¹⁰ Center for Thrombosis and Hemostasis, University Medical Center Mainz, Germany; Department of Cardiology,
30	Democritus University of Thrace, Greece
31	¹¹ Icahn School of Medicine at Mount Sinai; New York, NY
32	¹² David Geffen School of Medicine at UCLA, Los Angeles, CA
33	¹³ University College Dublin School of Medicine, Mater Misericordiae University Hospital, Dublin, Ireland, Royal
34	College of Surgeons in Ireland

- 35 ¹⁴The PERT Consortium[™], Nashua, NH
- 36 ¹⁵Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA
- 37 ¹⁶US Food and Drug Administration, Silver Spring, MD
- 38 ¹⁷ Beth Israel Deaconess Medical Center, Boston, MA
- 39 ¹⁸University Hospital of Wales and Cardiff University
- 40 ¹⁹Weill Cornell Medicine, Department of Radiology, New York, NY
- 41 ²⁰ Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
- 42 ²¹Department of Medicine, The Ottawa Hospital; University of Ottawa, Ottawa, ON
- 43

44 CORRESPONDING AUTHOR

- 45 Kenneth Rosenfield, MD, MSc
- 46 <u>Krosenfield1@mgh.harvard.edu</u>
- 47 <u>krosenfield@fastmail.us</u>
- 48 55 Fruit Street
- 49 Boston, MA 02114
- 50

51 Word Count: 4767

52 **Disclaimer** — This article reflects the consensus views of the writing group and does not necessarily represent the

- practices, policies, requirements or recommendations of the FDA. Further, the use of the word "required", "must" or
- 54 "should" in the document is not intended to indicate an FDA requirement.
- 55

56 **Disclosures**

- 57 Dr. Rosenfield reports consult fees from Abbott Vascular, Angiodynamics, Inc., Auxetics,
- 58 Becton-Dickinson, Boston Scientific, Inc., Contego, Imperative Care, Johnson & Johnson,
- 59 Biosense Webster, Medtronic, Neptune Medical, Philips, Surmodics, and Terumo, Board
- 60 Member for The PERT Consortium[™], and stock or stock options in Access Vascular, Aerami,
- 61 Althea Medical, Auxetics, Contego, Endospan, Imperative Care, Innova Vascular, InspireMD,
- 62 JanaCare, Magneto, MedAlliance, Neptune Medical, Orchestra, Prosomnus, Sealonix,
- 63 Shockwave, Skydance, Summa Therapeutics, Thrombolex, Valcare, Vantis Vascular, Vasorum,
- 64 and Vumedi.
- 65 Dr. Bowers reports consulting fees from Truvic, Inc., lecture fees from Janssen and BMS-Pfizer,
- 66 payment for expert testimony, participation on Advisory Board of Truvic, Inc.
- 67 Dr. Barnett reports payment for expert testimony.

- 68 Dr. Davis reports travel support for attending the Pulmonary Embolism Research Collaborative
- 69 meeting.
- 70 Dr. Giri reports research support from Boston Scientific, Inc. and Inari Medical, consulting fees
- from Boston Scientific, Inc., Cordis, and Abbott Vascular, support for attending meetings from
- 72 Inari Medical, participation on an Advisory Board for Angiodynamics, Inc. and Boston
- 73 Scientific, Inc., participation in leadership at SCAI and The PERT ConsortiumTM, and stock or
- 74 stock options in Endovascular Engineering.
- 75 Dr. Horowitz reports research support from Inari Medical, consultation and personal lecture fees
- ⁷⁶ from Inari Medical and Penumbra, Inc., and support for attending meetings from Inari Medical.
- 77 Professor Dr. Huisman reports no conflicts of interest.
- 78 Professor Dr. Hunt reports no conflicts of interest.
- 79 Dr. Keeling reports consulting fees from Angiodynamics, Inc., Penumbra, Inc., Viz.ai, and
- 80 Dexcom.
- 81 Dr. Kline reports no conflicts of interest.
- 82 Professor Dr. Klok reports institutional research support from Bayer, Bristol-Myers Squibb,
- 83 Actelion, Boston Scientific, Inc, Leo Pharma, The Netherlands Organisation for Health Research
- and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation, and the
- 85 Horizon Europe program, service on the Board of the Rembrandt Institute of Cardiovascular
- 86 Science, Chair of the Board of the Dutch Society of Vascular Medicine, nucleus member of the
- 87 ESC work group on pulmonary circulation and RV function, nucleus member of ISTH SSC
- 88 diagnostic and predictive variables, Chair of the Board of the Dutch Thrombosis Network, and
- 89 medical lead Anticoagulation Clinic Leiden.
- 90 Professor Dr. Konstantinides reports personal and institutional consulting fees from Bayer AG,
- 91 Daiichi-Sankyo, and Boston Scientific, Inc., and personal lecture fees from Bayer AG, Daiichi-
- 92 Sankyo, Pfizer Bristol-Myers Squibb, and Boston Scientific, Inc.
- 93 Ms. Lanno reports no conflicts of interest.
- 94 Dr. Lookstein reports consulting fees from Penumbra, Inc., Boston Scientific, Inc., Medtronic,
- 95 Cordis, Becton Dickinson, Abbott Vascular, Neptune Medical, Imperative Care, and Aidoc,
- payment for expert testimony, participation on Advisory Board for Magneto, Boston Scientific,
- 97 Inc., Medtronic, and Trireme, leadership roles at The PERT ConsortiumTM, CLI Global Society,

98 and Society of Interventional Radiology, stock or stock options in Imperative Vascular,

- 99 Thrombolex, Innova Vascular, and Summa Vascular.
- 100 Dr. Moriarty reports research support from Angiodynamics, Inc. and Penumbra, Inc., consulting
- 101 fees from Angiodynamics, Inc, Penumbra Inc., Inquis Medical, Innova Vascular, Boston
- 102 Scientific Inc., Auxetics, and Retriever Medical, and participation on the data safety monitoring
- 103 board for Penumbra, Inc.
- 104 Professor Dr. Ní Áinle reports institutional research support from Sanofi, Daiichi-Sankyo, the
- 105 Irish Health Research Board, Bayer, and Boston Scientific, Inc., patents pending for European
- 106 Application No. 20166826.6, past member of World Thrombosis Day International Steering
- 107 Committee, Director at Large and Member, INVENT Council, Co-Director, InVite, Co-Founder
- and member of Executive Committee of VTE Ireland, Advisory Committee for ACHM, Member
- 109 of "Preventing venous thromboembolism in hospitals" Collaborative Advisory Group, Board
- 110 Member, Thrombosis Ireland Patient Organization and Charity, and National Lead, Irish VTE
- 111 Patient Safety Programme.
- 112 Ms. Reed reports no conflicts of interest.
- 113 Dr. Rosovsky reports research support from BMS and Janssen, consulting fees from Abbott,
- BMS, Dova, Inari Medical, Janssen, and Penumbra, Inc., participation on the data safety
- 115 monitoring board for the Pepper Trial and Harvard Cancer Center, unpaid President-Elect of the
- 116 PERT Consortium and unpaid member of ASH Committee on Quality.
- 117 Dr. Royce reports no conflicts of interest.
- 118 Dr. Secemsky reports research support from NIH/NHLBINIH/NHBLI K23HL150290, Food &
- 119 Drug Administration, BD, Boston Scientific, Inc., Cook Medical, CSI, Laminate Medical,
- 120 Medtronic, and Philip, consulting fees and personal lecture fees from Abbott, Bayer, BD, Boston
- 121 Scientific, Inc., Cook, CSI, Inari Medical, Medtronic, Philips, Shockwave, and VentureMed, ad
- 122 participation on data safety monitoring boards for LIFE BTK, BIOMIMCS3D, HI-PEITHO, and
- 123 Transcend.
- 124 Professor Dr. Sharp reports consulting and lecture fees from Medtronic, Boston Scientific, Inc.,
- 125 Philips, Recor Medical, and Penumbra, Inc.
- 126 Dr. Sista reports research support from NIH/NHLBI as principal investigator of U34 and UG3
- 127 awards, unpaid participation on data safety monitoring boards for Angiodynamics, Inc. and

- 128 Thrombolex, Inc., and participation on the Board of Directors for the Society of Interventional
- 129 Radiology.
- 130 Dr. Smith reports no conflicts of interest.
- 131 Dr. Wells reports participation on the data safety monitoring board for Anthos.
- 132 Ms. Yang reports no conflicts of interest.
- 133 Dr. Whatley reports no conflicts of interest.

134

135

136 ABSTRACT

137

Recent advances in therapy and the promulgation of multidisciplinary pulmonary embolism 138 teams (PERTs) show great promise to improve management and outcomes of acute pulmonary 139 embolism (PE). However, the absence of randomized evidence and lack of consensus leads to 140 tremendous variations in treatment and compromises the wide implementation of new 141 innovations. Moreover, the changing landscape of healthcare, where quality, cost, and 142 accountability are increasingly relevant, dictates that a broad spectrum of outcomes of care must 143 be routinely monitored to fully capture the impact of modern PE treatment. We set out to 144 standardize data collection in PE patients undergoing evaluation and treatment, and thus 145 establish the foundation for an expanding evidence base that will address gaps in evidence and 146 inform future care for acute PE. To do so, over 100 international PE thought leaders convened in 147 Washington, DC in April 2022 to form the Pulmonary Embolism Research Collaborative (148 PERCTM). Participants included physician experts, key members of the United States Food and 149 Drug Administration (FDA), patient representatives, and industry leaders. Recognizing the 150 151 multi-disciplinary nature of PE care, the Pulmonary Embolism Research Collaborative (PERCTM) was created with representative experts from stakeholder medical subspecialties, 152 153 including cardiology, pulmonology, vascular medicine, critical care, hematology, cardiac surgery, emergency medicine, hospital medicine, and pharmacology. A list of critical evidence 154 155 gaps was composed with a matching comprehensive set of standardized data elements; these data points will provide a foundation for productive research, knowledge enhancement, and 156 157 advancement of clinical care within the field of acute PE, and contribute to answering urgent unmet needs in PE management. Evidence produced through PERCTM, as it is applied to data 158 159 collection, promises to provide crucial knowledge that will ultimately produce a robust evidence 160 base that will lead to standardization and harmonization of PE management and improved 161 outcomes.

162

163 CLINICAL PERSPECTIVE

164 1) What is new?

- 165 166 167
- Recent advances have increased options for treatment of acute pulmonary embolism, yet there remain wide variations in management due to the lack of a reliable evidence base upon which to base therapeutic decisions.

168 169			
109			
171			
172			
173			
174		base and enhancing care.	
175		clinical implications?	
176		zing collection of data for acute pulmonary embolism will enable analyses	
177 178		nform optimal risk stratification, treatment, and follow-up of patients with y embolism, and provide evidence-based treatment algorithms that will	
179	improve o		
180	-	created using the proposed standardized elements will enable	
181		king and quality assurance for clinicians caring for pulmonary embolism	
182	patients.		
183		tion of comprehensive standardized data elements into FDA IDE trials will	
184 195	enable the devices.	Agency to better assess the safety and effectiveness of investigational	
185 186	devices.		
100			
187	ABBREVIATIONS		
188			
189	AI	Artificial Intelligence	
190	AC	Anticoagulation; Anticoagulant	
191	CBT	Catheter-based Thrombectomy	
192	CDL	Catheter-directed Thrombolysis	
193	CDER	Center for Drug Evaluation and Research	
194	CDRH	Center for Devices and Radiological Health	
195	CPET	Cardiopulmonary Exercise Testing	
196	CTEPD	Chronic Thromboembolic Pulmonary Disease (also referred to as CTED)	
197	СТЕРН	Chronic Thromboembolic Pulmonary Hypertension	
198	ECMO	Extracorporeal Membrane Oxygenation	
199	EMR	Electronic Medical Record	
200	ESC	European Society of Cardiology	
201	FDA	Food and Drug Administration	
202	MCS	Mechanical Circulatory Support	
203	PE	Pulmonary Embolism	
204	PERC	Pulmonary Embolism Research Collaborative	

- 205 **PERT** Pulmonary Embolism Response Team
- 206 **PRO** Patient Reported Outcome
- 207 VTE Venous Thromboembolism

208

209 INTRODUCTION

Acute pulmonary embolism (PE) is a major source of cardiovascular morbidity and 210 mortality and a leading cause of preventable in-hospital death in the US and around the world.¹⁻⁷ 211 Despite its high prevalence, clinical impact, and considerable public health implications, there 212 remains a lack of consensus regarding what constitutes the optimal strategy for management of 213 214 acute PE. The significant variability in the application of newer treatment modalities highlights the lack of consensus and need for standardization. Unlike myocardial infarction (MI) and 215 216 stroke, for which robust evidence has led to consistent and standardized treatment, the absence of level I evidence regarding the management of PE has resulted in large variations in care. Further 217 exacerbating this variability is the fact that PE is managed by several different specialties, each 218 of which brings its own perspective and bias. 219

The most important reason for variability in treatment lies in the evidence gap that exists regarding optimal risk stratification and related risk-based management strategies, standardization of indication and application of interventional advanced PE treatment, and widely-accepted measures regarding outcomes of care for PE. Recent advances in treatment and availability of novel catheter directed techniques underscores the need for standardization of data collection in routine care, which is essential to understand their impact.

A core set of outcome measures for venous thromboembolism (VTE) was recently 226 proposed by the International Consortium for Health Outcomes Measurement (ICHOM); 227 228 however this set does not include relevant data elements regarding risk stratification and details of management decisions and is therefore insufficient to guide the much needed process of 229 harmonization and standardization of PE management.^{8, 9} The Pulmonary Embolism Research 230 Collaborative (PERCTM) was conceived as a forum to develop a pragmatic core set of data 231 elements, with common standards and definitions, that will serve as the foundation for data 232 233 collection regarding the evaluation, treatment, outcomes, and follow up. The evidence generated 234 by collecting such standardized data will enable analyses that will enhance clinical care, establish quality metrics, and promote research endeavors. 235

236

237 METHODOLOGY

238 $PERC^{TM}$ composition

239 An international group of multidisciplinary experts in PE convened to work in collaboration with the United States Food and Drug Administration (FDA), patient 240 241 representatives, healthcare organizations, and industry leaders, to explore gaps in recognition, diagnosis, treatment, and follow up of patients with acute PE. (Figure 1) PERCTM healthcare 242 contributors represented the multidisciplinary character of PE care and included international 243 representative experts from stakeholder medical subspecialties and scientific societies, including 244 cardiology, pulmonology, vascular medicine, critical care, hematology, cardiac surgery, 245 emergency medicine, hospital medicine, and pharmacology. Physician thought leaders were 246 invited to participate based on their past contribution to PERT efforts as well as their 247 involvement in contemporary trials for PE. Individuals invited to participate in PERC each 248 obtained institutional approval to participate. FDA representatives received endorsement to 249 250 participate on behalf of the Agency.

251

252 $PERC^{TM}$ objectives

The three objectives of PERC were: 1) to identify the current major evidence gaps that 253 254 must be closed in order to better inform care providers and reduce variations in PE care; 2) to identify what data capture will be necessary to close those gaps; and 3) to develop consensus 255 256 regarding a set of core set of data elements to be captured in routine care in all patients treated for PE. Ultimately, this initiative was to generate a comprehensive compendium of data elements 257 pertaining to how patients are risk-stratified and treated, and to capture outcomes. Notably, 258 PERCTM was not intended to establish recommended algorithms or guidelines for care. 259 260 Ultimately, analyses derived from databases utilizing these standardized elements proposed by PERCTM will: a) establish the relative value and utility of current risk stratification tools; b) 261 262 illuminate additional factors that may influence care and outcome, perhaps leading to creation of new tools for prognostication; c) enable more standardized and balanced assessment of outcomes 263 264 using different therapeutic approaches; d) provide meaningful evidence to inform future guidelines and care algorithms. 265

266

267 $PERC^{TM}$ methodology and procedures

Five working groups (**Figure 2**), based on timing relative to patient presentation and intervention, were formulated before the meeting and leaders representing different disciplines

were selected for each. Groups were charged with developing consensus around a set of data elements for capture pertaining to important knowledge gaps. In order to maximize productivity at the on-site PERCTM meeting, groups were asked to prepare their respective work product in advance. Accordingly, in the weeks leading up to the PERCTM meeting day, group leaders convened a series of workgroup virtual meetings. During the meeting, these proposed gaps in evidence and relevant data elements were discussed and finalized.

276

277 Establishment of list of data elements

Data elements throughout the entire "PE journey", from presentation through discharge, 278 and into follow up were considered in order to assess the various management strategies, 279 decisions, and care rendered for acute PE, and the impact of these on outcomes. The timeline 280 was divided into 5 distinct serial "events" representing milestones in the journey (Figure 2). 281 Alternative (exploratory) elements not included in prior data collection efforts were considered, 282 which could ultimately be relevant and predictive or influence outcomes, and therefore be 283 important to capture. Elements were grouped into categories of "core" (i.e. absolutely necessary) 284 285 and "enhanced" (i.e. beneficial to know for research and exploratory purposes). There was specific emphasis on identifying data elements that are pragmatic, such that they could be 286 287 captured according to consensus definitions and at appropriate time points, with good ascertainment. 288

Practicable definitions that could be applied across institutions and easily understood by a broad professional audience were applied when available. Consideration was given to whether it was realistic to expect participating clinicians or institutions, during routine patient care, to collect the data element in a standardized manner. Evidence derived from the existing medical literature was used to justify final recommendations.

294

295 *Data sharing*

An important concept in collection of data regarding PE from a broad base, as is expected in tools utilizing the PERC elements, is an agreement that data-sharing should be enabled to the extent that is legally and ethically possible. As such, users who share the common elements and definitions established by PERC will be encouraged to share de-identified data and thus enhance

the overall dataset, enabling large-scale analyses that will increase the evidence base surroundingcare of PE.

302

303 **RESULTS**

Discussion in the working groups and during the PERCTM meeting resulted in concentration on focused topics, including the current gaps in evidence and the need for specific data element capture.

307 *Gaps in Evidence*

After discussion in the working groups and during the PERCTM meeting, twelve crucial gaps in evidence were established as being the most important drivers of current variations in PE management and challenges that need to be overcome to improve the outcomes of care. (See **Table 1).** The gaps in evidence shown in were the driver of the selection and definition of data elements. An important unmet need addressed by the PERCTM experts was to clarify the roles of patient education, shared decision-making, and patient reported outcomes (PRO) within treatment paradigms.

315

316 *List of Data Elements*

During the PERCTM meeting, 351 data elements were identified and defined. The final list of data elements listed fully in **Appendix 1** represent the ultimate output of the PERCTM meeting. For all data elements, the status (core versus enhanced) is indicated, as well as a definition, relevant side notes (e.g. relevant metadata standards) and/or a supporting reference where appropriate. The highlights of this list of data elements are detailed below.

The initial assessment includes common demographic parameters, risk factors and 322 323 clinical details. Demographic elements determined to be of particular importance include sex assigned at birth (male, female, or other) and separate elements for race and ethnicity, based on 324 recommendations from the Office of Minority Health.¹⁰ Standards for collection of race and 325 ethnicity information are delineated on a prior document from the FDA entitled "Collection of 326 Race and Ethnicity Data in Clinical Trials"¹¹. Patient-level zip code is recommended as an 327 important potential covariate for socioeconomic characterization, as is insurance status. This 328 information is important to capture and evaluate, as health disparities in management of PE 329

hospitalizations and PE follow-up, based on race^{12, 13}, gender^{14, 15}, and socioeconomic status¹⁶ have been reported.

332 Presenting clinical symptoms include those routinely endorsed by the patient on initial evaluation. Particular attention should be paid to the duration of PE symptoms (in days), as this 333 may have significant interactions with the risk/benefit profiles of various PE therapeutics. Vital 334 signs on admission and at various time points thereafter are relevant. Elements associated with 335 hemodynamic compromise (e.g. cardiac arrest, hypotension requiring vasopressors, need for 336 mechanical circulatory support) as well as respiratory compromise (e.g., requiring supplemental 337 oxygen or mechanical ventilation) are captured. The recommended elements will enable 338 calculations of various prognostic PE risk scores, including the sPESI score, Bova scores, 339 National Early Warning Score and others.¹⁷⁻²⁰ For that purpose, specific quantitative values of 340 key laboratory tests are to be captured. For the same reason, the data elements also include 341 details of initial imaging evaluations, including PE-protocol computed tomographic (CT) 342 imaging and transthoracic echocardiography, performed either by a trained ultrasonographic 343 technician/echocardiologist or as a point-of-care ultrasound (POCUS) by a physician or other 344 345 qualified provider. Data elements associated with an escalation of care therapy, resulting in an (interventional) reperfusion procedure, should be captured, including all treatment pathways, 346 347 along with specific parameters for each selected treatment approach. For all patients, typical procedural parameters, as well as baseline information that may inform the primary treatment 348 349 decision, should be considered. These include, among others, date and time of PERT activation, the specialties involved in the team, and the presence of any known contraindication to 350 351 anticoagulation and/or thrombolysis. For catheter-based therapies, such as catheter-directed thrombolysis (CDT) and catheter-based thrombectomy (CBT), complete device information, 352 353 including either the unique device identifier (UDI) or brand, model and size, is pertinent. The exact location of treatment, access site information, and vascular closure information should be 354 355 collected. For CDT, the drug type, dose, administration strategy (i.e., bolus vs infusion), and duration of treatment is essential. For CBT, whether the procedure entailed aspiration, 356 357 mechanical disruption, or a combination is important. All elements related to the exact device 358 type, treatment details, and drugs/dosages are considered core.

359 Procedure timing, specifically how to define the initiation of therapy and events related to 360 a therapeutic intervention, is an important consideration and must be captured in order to enable

accurate post-hoc analysis to evaluate and compare therapies. Given that specific data elements 361 are being recommended to be conducted at various time points, the "start time" needs to be 362 363 defined. This may be different for various therapies administered and, in the event that more than one therapy is administered, separate start times should be documented for each, rather than the 364 whole "procedure." For pharmaceutical treatments, including anticoagulation and systemic 365 thrombolysis, the initiation of therapy is defined as the time when the drug is administered. For 366 other device-based therapies, the initiation of therapy is defined as the time of venous access for 367 the intervention. Specific focus is not placed on "door to catheter time," though this should be 368 calculable, as this has been reported that reduction of this time has a favorable impact on 369 outcomes²¹. End of therapy is also captured, defined as follows: 370

371 - Oral anticoagulation– After administration of the first oral agent

372 - Parenteral anticoagulation– After injection of the first agent

373 - Systemic Thrombolysis – After the infusion is discontinued

374 - Catheter-based thrombolysis – After the completion of the lytic infusion

375 - Catheter-based thrombectomy – After leaving the angiographic suite

376 - Surgical thrombectomy – After leaving the operating room

377

Definitions for acute clinical success, which may differ based on the hemodynamic status 378 of the patient, are summarized in **Table 2** and provide more detail to the definition of treatment 379 success as suggested by the European Society of Cardiology.²² It is recognized that not achieving 380 one or more of these definitions within 48 hours does not necessarily reflect that clinical 381 improvement will not or has not partially been achieved (i.e., stabilized patient on ECMO 382 support for >48 hours). However, to associate hemodynamic improvement with a therapeutic 383 intervention requires proximity to the procedure (within 48 hours, by consensus of the group). It 384 is recognized that not achieving one or more of these endpoints within 48 hours does not 385 necessarily reflect that clinical improvement will not or has not partially been achieved (i.e., 386 387 stabilized patient on ECMO support for >48 hours). However, to associate hemodynamic improvement with a therapeutic intervention requires proximity to the procedure (within 48 388 389 hours, by consensus of the group).

390 Definitions for treatment failure and treatment-associated complications were agreed 391 upon as well and illustrated in **Table 3**. Post-discharge management includes the collection of

392 specific data elements post-discharge, such as adverse events (e.g. recurrent venous 393 thromboembolism or bleeding), and hospital readmission rates at 30 days and 90 days after 394 hospital discharge. Functional status and quality of life issues are considered part of this 395 evaluation, even beyond the initial 3-month follow-up period, as well as the stepwise evaluation 396 of patients for the development of chronic thromboembolic pulmonary hypertension (CTEPH) or 397 chronic thromboembolic pulmonary disease (CTEPD).²³⁻²⁷

Lastly, the data elements include indicators of information having been provided for education of the patient and his/her family, in particular regarding the use of anticoagulant drugs.

401 **DISCUSSION**

Large gaps in the evidence base regarding management of PE have resulted in substantial 402 variations in care. Identification and capture of appropriate data elements during the journey of 403 the PE patient, from presentation to discharge and into follow-up, will be critical to expansion of 404 the evidence base and represent the first step towards a more pragmatic and evidence-based 405 approach to patient care in this rapidly evolving field. The current document establishes a 406 baseline of relevant data elements, generated by consensus of the Pulmonary Embolism Research 407 Collaborative (PERCTM) in conjunction with FDA, that are appropriate to collect during the PE 408 patient journey. Elements are included on the basis of their known or potential effect on outcome 409 and are designated as either "core" or "enhanced". The core set represents the minimum 410 necessary elements for capture, while the enhanced set includes additional parameters that may 411 be useful to inform future understanding of PE and influence treatment strategies. Analysis of 412 these data will enlighten the medical community and provide guidance regarding current best 413 practices, and will serve as the foundation for improving therapies moving forward. While 414 establishing a standardized set of data elements was the main objective of the PERCTM, another 415 416 key objective of the initiative was for the expert collaborators to collectively identify the shortcomings and data gaps in PE care. 417

During the course of the PERCTM deliberations, in addition to identifying specific elements worthy of capture, several important considerations were identified that affect PE data collection. Addressing each of these will be important as part of the effort to expand the PE evidence base and close the knowledge gap regarding optimal management.

422 Threshold for Activation and Data Capture

The "spectrum of PE", or the varying degrees in which this disease presents, is an 423 424 acknowledged phenomenon and is a function of many variables. The threshold for various treatments, based on this spectrum, is not well defined. Similarly, the threshold for full PERT 425 426 activation is not standardized in regard to this spectrum. Indeed, the significant variations in care were the stimulus for promoting the team-based concept of PE care (PERTs) and are one of the 427 most compelling reasons for collecting and analyzing patterns of PE care in a registry. 428 Acknowledging the variations in presentation and severity of PE, the data elements 429 recommended for capture herein may not be necessary or appropriate for every patient with acute 430 PE. 431

432

433 *Statistical Analysis*

434 Data acquired through registries and other sources using the PERC template and definitions will be subjected to rigorous review as a part of all subsequent analyses. 435 Missingness, which plagues many registry databases, will be addressed as part of this review. 436 The pragmatism of fully capturing data elements will be affected by many factors, including then 437 number and complexity of the elements identified, the resources available at the point of 438 collection, and the level of ascertainment required by the respective registry or collection tool. 439 The data elements recommended for capture within this document represent a comprehensive list 440 of those that were identified as minimally necessary elements (i.e. core) or those which provide 441 for more detailed analysis or are exploratory regarding their impact on outcome (i.e. enhanced). 442 443 Both core and enhanced data may be useful to inform future understanding of PE and influence treatment strategies. It is acknowledged that these constitute a long list of elements, which may 444 445 be challenging to capture fully and comprehensively. It is also understood that, as the list of elements for capture increases, the potential for increase in missing data also exists. Appropriate 446 447 data ascertainment is important since significant missing data will hinder the data evaluation and analytic process. Thus, the intention of this document is to emphasize capture of the core 448 449 elements. Data quality and integrity and the value of the subsequent statistical analyses will rely 450 upon identification of the most critical (i.e. essential) elements and sufficient ascertainment 451 thereof.

452

453 Data Collection Timepoints

The timing and, more importantly, the frequency with which data elements should be 454 455 captured for input into any registry or clinical trial database is an important consideration. PE patients represent a wide spectrum of severity and, therefore, the level of monitoring and data 456 457 capture will vary as well. For example, a patient with a recent cardiac arrest would be receiving real-time electronic monitoring with continuous recording of data from oxygen saturation probes, 458 459 arterial blood pressure recording lines, and respiratory rates. Whereas, a patient who is stable and 460 minimally symptomatic may be admitted to a standard medical floor and only have clinical observations documented every six hours. It would not be appropriate to expect those respective 461 462 frequencies to be required for capture and, on the other hand, a less rigorous approach might fail

463 to capture important and relevant information. To strike a balance, it was felt that observations on all patients should be recorded and inputted to registries at a minimum of once per day, with 464 465 more intense requirements for those at the more critical end of the spectrum. Of course, this is conjecture and the ideal timepoints are yet to be understood. An ability to interface national PE 466 registries with electronic medical records (EMR) may be helpful in this respect, as software 467 468 bridges could be written that allow automated extraction of clinical observations data from the EMR source. This remains to be further explored, as ongoing expansion of the evidence base 469 sheds light on optimal timepoints and intervals for data collection. 470

471

472 Use of AI for Data Capture

Artificial Intelligence (AI) is playing an increasingly important role in facilitating the diagnosis and management of acute PE. Machine learning algorithms can expedite and enhance the detection of PE on CT scans, as well as the presence of echocardiographic findings such as RV strain. Further, AI programs can integrate clinical data to define risk scores and facilitate decision-making. Ultimately, AI may not only inform the clinical team and guide management but may also suggest new management paradigms based on input from outcomes combined with computer mediated "deep learning."

480 Current AI programs access raw data from imaging modalities and subject those data to 481 analysis to define presence of a PE and its characteristics. AI programs are now establishing 482 communication pathways with electronic medical records, allowing for assimilation of patient 483 data (including laboratory values, clinical information, and test results). Integration of these data, 484 when subjected to AI tools such as machine and deep learning, will provide a more 485 comprehensive analysis of patient risk, clinical status, and optimal treatment.

AI will be a powerful tool to optimize data capture and provide a more robust evidence 486 487 base for PE. During the process of accessing and organizing raw data from imaging modalities 488 and the electronic medical record, these programs can be utilized to automatically populate PE databases. By enabling data collection "in the background," AI will provide more standardization 489 of data collection, reduce subjectivity, ensure more consistency in interpretation, and reduce 490 "missingness" (enhance ascertainment). Beyond this, deep ("cognitive") learning extrapolated 491 from these data will add a new dimension to the evidence base and ultimately enhance the 492 493 treatment paradigms for PE, through more accurate calculation of existing risk scores, creation of

494 novel, more comprehensive risk calculators, and establishment of increasingly effective care495 pathways.

496

497 Partnership with FDA

FDA has been an active participant in this project and shares common goals of 498 optimizing care, improving outcomes, and ensuring safety and efficacy in the care of PE patients. 499 The challenges facing treating clinicians are similar to the questions that regulatory experts 500 grapple with when evaluating the risk-benefit profile of new PE devices and treatment strategies. 501 FDA is committed to least burdensome approaches²⁸ to marketing applications. Better 502 understanding of decision-making surrounding escalation and use of advance therapies, as well 503 as the relative effectiveness of various treatment strategies in different PE populations, can 504 inform regulatory strategies, potentially streamline the availability of effective new treatments, 505 and foster innovation in the care of the PE patient. Ongoing participation of regulatory agencies 506 in PERCTM, coupled with an associated robust registry, provides an opportunity to assist in 507 regulatory decision making. This supports the FDA's priority to advance the use of real-world 508 evidence (RWE)^{29, 30}. 509

510

511 CONCLUSION

The PERCTM initiative was designed to identify gaps in the knowledge base regarding 512 513 care of pulmonary embolism and to establish a standardized set of data elements to collect in patients with PE. Utilization of the elements identified and defined by PERCTM within registries 514 515 and clinical trials, with appropriate data-sharing arrangements, will enable coalescence of data to perform large-scale analyses that will expand the evidence base for PE and ultimately inform 516 517 best practices. Engagement of multispecialty physicians, device manufacturers, pharmacological experts, patient advocates, as well as regulatory representatives from both device and drug 518 519 agencies in the PERCTM process enabled a broad-based understanding of the evidence gaps. PERC[™] has set the stage to address these evidence gaps and promote progress in PE care. 520

521

522 ACKNOWLEDGEMENTS

523

- 524 We would like to acknowledge the contributions from all attendees at the inaugural PERC^{TMTM}
- 525 meeting held in Washington DC on April 22, 2022 (Appendix 2).
- 526

527 SOURCES OF FUNDING

- 528 None
- 529
- 530 **DISCLOSURES**
- 531 Submitted separately
- 532
- 533 APPENDICES
- 534
- 535 Appendix 1 Core and Enhanced Data Elements for Collection in Acute PE Patients
- 536 See attached Excel spreadsheet
- 537 Appendix 2 Inaugural PERCTM Meeting Contributors
- 538 See attached Word document
- 539
- 540


541 **REFERENCES**

- Sedhom R, Megaly M, Elbadawi A, Elgendy IY, Witzke CF, Kalra S, et al. Contemporary national trends and outcomes of pulmonary embolism in the united states. *Am J Cardiol*. 2022;176:132-138
- Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease
 and stroke statistics-2018 update: A report from the american heart association. *Circulation*.
 2018;137:e67-e492
- 5483.Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb549Thrombolysis. 2016;41:3-14
- 5504.Smith SB, Geske JB, Kathuria P, Cuttica M, Schimmel DR, Courtney DM, et al. Analysis of national551trends in admissions for pulmonary embolism. Chest. 2016;150:35-45
- 5525.Barco S, Mahmoudpour SH, Valerio L, Klok FA, Munzel T, Middeldorp S, et al. Trends in mortality553related to pulmonary embolism in the european region, 2000-15: Analysis of vital registration554data from the who mortality database. Lancet Respir Med. 2020;8:277-287
- 5556.Barco S, Valerio L, Ageno W, Cohen AT, Goldhaber SZ, Hunt BJ, et al. Age-sex specific pulmonary556embolism-related mortality in the USA and canada, 2000-18: An analysis of the who mortality557database and of the cdc multiple cause of death database. Lancet Respir Med. 2021;9:33-42
- Huisman MV, Barco S, Cannegieter SC, Le Gal G, Konstantinides SV, Reitsma PH, et al. Pulmonary
 embolism. *Nat Rev Dis Primers*. 2018;4:18028
- Second Sec
- 5649.de Jong CMM, Rosovsky RP, Klok FA. Outcomes of venous thromboembolism care: Future565directions. J Thromb Haemost. 2023;21:1082-1089
- 10. U.S. Department of Health and Human Services Office of Minority Health. Homepage. 2022
- 567 11. U.S. Food and Drug Administration Communication. Collection of race and ethnicity data in568 clinical trials. 2016
- 56912.Martin KA, McCabe ME, Feinglass J, Khan SS. Racial disparities exist across age groups in illinois570for pulmonary embolism hospitalizations. Arterioscler Thromb Vasc Biol. 2020;40:2338-2340
- Phillips AR, Reitz KM, Myers S, Thoma F, Andraska EA, Jano A, et al. Association between black
 race, clinical severity, and management of acute pulmonary embolism: A retrospective cohort
 study. J Am Heart Assoc. 2021;10:e021818
- Pribish AM, Beyer SE, Krawisz AK, Weinberg I, Carroll BJ, Secemsky EA. Sex differences in
 presentation, management, and outcomes among patients hospitalized with acute pulmonary
 embolism. *Vasc Med*. 2020;25:541-548
- Agarwal S, Clark D, 3rd, Sud K, Jaber WA, Cho L, Menon V. Gender disparities in outcomes and
 resource utilization for acute pulmonary embolism hospitalizations in the united states. *Am J Cardiol.* 2015;116:1270-1276
- Wadhera RK, Secemsky EA, Wang Y, Yeh RW, Goldhaber SZ. Association of socioeconomic
 disadvantage with mortality and readmissions among older adults hospitalized for pulmonary
 embolism in the united states. J Am Heart Assoc. 2021;10:e021117
- 58317.Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, et al. Derivation and validation584of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172:1041-1046

585	18.	Bova C, Sanchez O, Prandoni P, Lankeit M, Konstantinides S, Vanni S, et al. Identification of
586		intermediate-risk patients with acute symptomatic pulmonary embolism. Eur Respir J.
587		2014;44:694-703
588	19.	RCoPo L. National early warning score (news): Standardising the assessment of acute-illness
589		severity in the nhs — report of a working party. Royal College of Physicians. 2012
590	20.	Bavalia R, Stals MAM, Mulder FI, Bistervels IM, Coppens M, Faber LM, et al. Use of the national
591		early warning score for predicting deterioration of patients with acute pulmonary embolism: A
592		post-hoc analysis of the years study. Emerg Med J. 2023;40:61-66
593	21.	Rawal A, Ardeshna D, Hesterberg K, Cave B, Ibebuogu UN, Khouzam RN. Is there an optimal
594		"door to cath time" in the treatment of acute pulmonary embolism with catheter-directed
595		thrombolysis? Ann Transl Med. 2019;7:419
596	22.	Pruszczyk P, Klok FA, Kucher N, Roik M, Meneveau N, Sharp ASP, et al. Percutaneous treatment
597		options for acute pulmonary embolism: A clinical consensus statement by the esc working group
598		on pulmonary circulation and right ventricular function and the european association of
599		percutaneous cardiovascular interventions. <i>EuroIntervention</i> . 2022;18:e623-e638
600	23.	Boon G, Barco S, Bertoletti L, Ghanima W, Huisman MV, Kahn SR, et al. Measuring functional
601		limitations after venous thromboembolism: Optimization of the post-vte functional status (pvfs)
602		scale. Thrombosis research. 2020;190:45-51
603	24.	Klok FA, Cohn DM, Middeldorp S, Scharloo M, Buller HR, van Kralingen KW, et al. Quality of life
604		after pulmonary embolism: Validation of the pemb-qol questionnaire. J Thromb Haemost.
605		2010;8:523-532
606	25.	Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, et al. Ers statement on chronic
607		thromboembolic pulmonary hypertension. Eur Respir J. 2021;57
608	26.	Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 esc/ers
609		guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J.
610		2022;43:3618-3731
611	27.	Morris TA, Fernandes TM, Channick RN. Evaluation of dyspnea and exercise intolerance after
612		acute pulmonary embolism. Chest. 2023;163:933-941
613	28.	U.S. Food and Drug Administration. The least burdensome provisions: Concept and principles.
614		2019
615	29.	U.S. Food and Drug Administration. Use of real-world evidence to support regulatory decision-
616		making for medical devices. 2017
617	30.	U.S. Food and Drug Administration. Real-world data: Assessing registries to support regulatory
618		decision-making for drug and biological products - guidance for industry. 2021
619	31.	Stein PD, Matta F, Goldman J. Obesity and pulmonary embolism: The mounting evidence of risk
620		and the mortality paradox. Thrombosis research. 2011;128:518-523
621	32.	Gauthier K, Kovacs MJ, Wells PS, Le Gal G, Rodger M, investigators R. Family history of venous
622		thromboembolism (vte) as a predictor for recurrent vte in unprovoked vte patients. J Thromb
623		Haemost. 2013;11:200-203
624	33.	Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 esc
625		guidelines for the diagnosis and management of acute pulmonary embolism developed in
626		collaboration with the european respiratory society (ers): The task force for the diagnosis and
627		management of acute pulmonary embolism of the european society of cardiology (esc). Eur
628		<i>Respir J.</i> 2019;54
629	34.	Budd AC, Rhodes M, Forster AJ, Noghani P, Carrier M, Wells PS. Prescribing patterns and
630		outcomes of venous thromboembolism prophylaxis in hospitalized medical and cancer patients:
631		Observations from the ottawa hospital. Thrombosis research. 2021;197:144-152

632	35.	Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a
633		first episode of venous thromboembolism: A systematic review. <i>Blood</i> . 2013;122:817-824
634	36.	Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. Identifying unprovoked
635		thromboembolism patients at low risk for recurrence who can discontinue anticoagulant
636		therapy. CMAJ. 2008;179:417-426
637	37.	de Winter MA, van Es N, Buller HR, Visseren FLJ, Nijkeuter M. Prediction models for recurrence
638		and bleeding in patients with venous thromboembolism: A systematic review and critical
639		appraisal. Thrombosis research. 2021;199:85-96
640	38.	Prins MH, Lensing AWA, Prandoni P, Wells PS, Verhamme P, Beyer-Westendorf J, et al. Risk of
641		recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv.
642		2018;2:788-796
643	39.	Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med.
644		2004;351:268-277
645	40.	Rosano GMC, Rodriguez-Martinez MA, Spoletini I, Regidor PA. Obesity and contraceptive use:
646		Impact on cardiovascular risk. ESC Heart Fail. 2022
647	41.	Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization
648		Committee of the International Society on T, Haemostasis. Definition of major bleeding in
649		clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb
650		Haemost. 2005;3:692-694
651	42.	Quigley N, Gagnon S, Fortin M. Aetiology, diagnosis and treatment of moderate-to-severe
652		haemoptysis in a north american academic centre. ERJ Open Res. 2020;6
653	43.	Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for
654		patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370:1402-1411
655	44.	The Joint Commission. National patient safety goal for anticoagulant therapy. 2018:1-4
656	45.	Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 esc
657		guidelines for the diagnosis and management of acute pulmonary embolism developed in
658		collaboration with the european respiratory society (ers). Eur Heart J. 2020;41:543-603
659	46.	Gaddh M, Rosovsky RP. Venous thromboembolism: Genetics and thrombophilias. Semin Respir
660		Crit Care Med. 2021;42:271-283
661	47.	Khair RM, Nwaneri C, Damico RL, Kolb T, Hassoun PM, Mathai SC. The minimal important
662		difference in borg dyspnea score in pulmonary arterial hypertension. Ann Am Thorac Soc.
663		2016;13:842-849
664		
665		

Figure 1: Multi-Disciplinary Experts contributing to Inaugural PERCTM Meeting



671

666

672

673

674

Table 1: Overview of critical gaps in evidence per stage of the PE journey

Initial assessment and acute treatment 1. What are, at initial assessment, the most relevant comorbidities, demographic parameters (including socioeconomic status), presenting symptoms, clinical signs, and (imaging) biomarkers for optimal risk stratification of acute PE? What combination of parameters should be utilized to produce the "ideal risk score"? What is the potential value/contribution of Artificial Intelligence (AI) in a) facilitating/accelerating diagnosis of PE, b) determining risk, c) coordinating care? 3. What are the various institutional approaches to PE? Is there multidisciplinary involvement? In which institutions are there formal teams (e.g., PERTs) and for which patients is that team involved? What is the influence, value, advantages, and disadvantages of the PERT approach? When is primary reperfusion therapy for acute PE indicated? 4. Interventional management, acute outcomes and adverse events What are the therapeutic outcomes (technical, procedural, and clinical success), safety profile, 5. and complications associated with (the combination of) various interventional and pharmacologic management strategies for PE? What is the role of ECMO and other hemodynamic support (e.g., Veno-veno bypass and RV 6. support systems) in the treatment of patients with acute PE? 7. How is treatment success of the different management strategies for PE defined? Hospital monitoring post-intervention 8. How (which clinical/biomarker/imaging parameters to measure, which scores to use), how often, and where should patients optimally be monitored during initial hospitalization and treatment? What combination of parameters should be utilized to produce the "ideal risk score"? 9. Where (department, type of hospital) are PE patients optimally managed? 10. Which parameters are appropriate to evaluate/measure prior to discharge and what values must be achieved to ensure safe discharge?

Post discharge management

11. What are the intermediate and long-term effects and outcomes of acute PE, and its treatment strategy, with respect to clinical complications, functional status, and quality of life?

12. What constitutes appropriate and optimal follow up care for patients with acute PE, including timing of reassessments and relevant parameters to measure? How might utilization of standardized follow-up algorithms influence management?

675

676

677

 Table 2: Definition of treatment success

Acute Outcome	Definition
Device success	Successful delivery of the device without device deficiency to the pulmonary artery, with subsequent function per IFU
Technical success	Successful delivery of designed intervention, whether evidence of successful thrombus removal or delivery of thrombolytic, in the absence of device deficiency
Procedural success	Both technical and clinical success are achieved
Acute clinical success- hemodynamically stable patients	Improvement within 48 hours of a therapeutic procedure including: 1) clinical improvement in vital signs (reduced O2 requirements without ambulation and/or improved HR), 2) symptomatic improvement (PR), 3) invasive physiologic improvement, 4) non-invasive imaging improvement
Acute clinical success- hemodynamically unstable patients 678	Improvement in hemodynamics within 48 hrs of a therapeutic procedure including resolution of unstable physiology as defined by one or more of the following: 1) resolution of hypotension, 2) removal of vasoactive drugs, 3) extubation, 4) decannulation from MCS

679

Table 3: Definition of treatment failure and complications of treatment

Adverse Event	Definition
Major bleeding	ISTH definition

	If a patient coughs up blood with sputum or has frank
Hemoptysis	bleeding into the airway. If present, classify into moderate or
	major
	Less than 50 mL of blood without the need for additional
Moderate hemoptysis	intervention
Major homontysis	Greater than 50 mL of blood with or without additional
Major hemoptysis	intervention
	A patient with intact neurologic function becomes agitated,
Impording requiretory emest	confused and struggles to breathe. Usually associated with
Impending respiratory arrest	tachycardia, diaphoresis and intercostal or sternoclavicular
	retractions
	Failure of a medical device to perform in accordance with its
Device malfunction	intended purpose when used in accordance with the
	instructions for use
	User action or lack of user action while using the medical
Device user error	device that leads to a different result than that intended by the
	manufacturer or expected by the user
Device Inadequacy of IFU	Insufficient or misleading information in the instructions for
Device madequacy of 11-0	use or labeling
	Undesirable damage to a medical device involving the loss of
	structural integrity, such as a partial or full thickness crack in
Device fracture/component separation	the device materials, or loss of adherence between device
	materials, resulting in an undesirable separation, breaking
	apart, or detachment of some part or piece(s) of the device
	Any persistent bleeding or hematoma in conjunction with the
Access site complication	need for transfusion, or access-site vascular injury requiring
	intervention (e.g. surgical or endovascular repair)
	Defined as one in the following: 1) need for cardiopulmonary
Clinical deterioration	resuscitation, 2) systolic blood pressure < 90 mm Hg for at
	least 15 min, 3) drop in systolic blood pressure by at least 40
	mm Hg for at least 15 minutes with signs of end-organ

	hypoperfusion (cold extremities or low urinary output < 30
	mL/h or mental confusion), 4) need for catecholamine
	administration to maintain adequate organ perfusion and a
	systolic blood pressure of > 90 mm Hg (including dopamine
	at the rate of > 5 microgram/kg per minute), 5) unplanned
	endotracheal intubation, 6) unexpected requirement for
	mechanical ventilation, 7) emergency surgical embolectomy
	Death directly related to the device, including from the
	following: 1) vascular or cardiovascular injury, 2) device
Device-related death at 48 hours	malfunction, 3) device-induce cardiac arrhythmia, 4)
	worsening pulmonary or right heart function (exclusive of
	worsening from recurrent PE)